EA200100153A1 - JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS - Google Patents

JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS

Info

Publication number
EA200100153A1
EA200100153A1 EA200100153A EA200100153A EA200100153A1 EA 200100153 A1 EA200100153 A1 EA 200100153A1 EA 200100153 A EA200100153 A EA 200100153A EA 200100153 A EA200100153 A EA 200100153A EA 200100153 A1 EA200100153 A1 EA 200100153A1
Authority
EA
Eurasian Patent Office
Prior art keywords
asat
atherosclerotic
defects
treatment
mmp inhibitors
Prior art date
Application number
EA200100153A
Other languages
Russian (ru)
Inventor
Томас Майкель Эндру Бокан
Original Assignee
Варнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер-Ламберт Компани filed Critical Варнер-Ламберт Компани
Publication of EA200100153A1 publication Critical patent/EA200100153A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Предмет данного изобретения составляет совместное назначение веществ, ингибирующих АСАТ и ММР, для понижения компонентов атеросклеротического поражения, связанных с макрофагами и с клетками гладких мышц, которое приводит к ослаблению экспансии существующих поражений и развития новых поражений, предупреждает отрыв бляшек и способствует регрессии поражений у млекопитающих.Отчет о международном поиске был опубликован 2000.05.18.The object of this invention is the joint appointment of ASAT and MMP inhibiting substances to reduce atherosclerotic lesion components associated with macrophages and smooth muscle cells, which leads to a weakening of the expansion of existing lesions and the development of new lesions, prevents plaque detachment and promotes regression of lesions in mammals. The international search report was published on 2000.05.18.

EA200100153A 1998-07-21 1999-06-18 JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS EA200100153A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
EA200100153A1 true EA200100153A1 (en) 2001-08-27

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100153A EA200100153A1 (en) 1998-07-21 1999-06-18 JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291D0 (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020050257A (en) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Prevention of Plaque Rupture by ACAT Inhibitors
DOP2000000107A (en) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP4606027B2 (en) * 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Carbamate compounds having piperazine bonds as HDAC inhibitors
JP4617449B2 (en) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド N-hydroxyamide derivative having antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CN1192140A (en) * 1995-08-04 1998-09-02 沃尼尔·朗伯公司 Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
KR20000011095A (en) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Nonphenyl sulfoneamide as inhibitor of matrix metalloproteinase
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
ID30030A (en) 2001-11-01
YU3501A (en) 2005-06-10
WO2000004892A3 (en) 2000-05-18
HRP20010055A2 (en) 2002-04-30
HUP0102880A3 (en) 2002-11-28
ZA200100294B (en) 2002-01-10
CZ2001126A3 (en) 2002-01-16
CN1310629A (en) 2001-08-29
NO20010291L (en) 2001-01-18
AU4701799A (en) 2000-02-14
IS5809A (en) 2001-01-12
WO2000004892A2 (en) 2000-02-03
IL140982A0 (en) 2002-02-10
BR9912296A (en) 2001-04-17
KR20010083134A (en) 2001-08-31
EE200100046A (en) 2002-06-17
JP2002521328A (en) 2002-07-16
CA2335062A1 (en) 2000-02-03
PL346011A1 (en) 2002-01-14
SK502001A3 (en) 2002-06-04
TR200100205T2 (en) 2001-05-21
OA11584A (en) 2004-07-20
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (en) 2001-01-18
HUP0102880A2 (en) 2002-06-29
BG105162A (en) 2001-12-29
EP1098662A2 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
EA200100153A1 (en) JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS
DE602004025030D1 (en) FUSSGELARTARTHROPLASTIE SYSTEM
DE1073432T1 (en) USE OF GLYCINE RECEPTORAGONISTS AND GLYCINE INHIBITOR INHIBITORS FOR THE TREATMENT OF NEUROPSYCHIATRIC COMPLAINTS
EA199900384A1 (en) DEVICE FOR CLEANING INTERSTENTAL INTERMEDIATE AND METHOD OF ITS MANUFACTURE
BR9813228A (en) Formulation of 2-methyl-thieno-benzodiazepine
DE69721554D1 (en) LOW RESIDUE AQUEOUS CLEANING AND DISINFECTANT FOR HARD SURFACES
DE29502880U1 (en) Endoscope for ultrasound echography
AU5624699A (en) Use of 5ht-6 antagonists
NO20000268L (en) Use of Lactobacillus for reduction of fibrinogen level in blood
DE69725052D1 (en) Connecting pin for multi-part orthopedic implant
EA200000536A1 (en) APPLICATION OF THE COMBINATION OF THE CONVERTER ENZYME INHIBITOR AND DIURETICS FOR THE TREATMENT OF MICROCIRCULATION DISORDERS
ID27544A (en) MUSCARINAT AGONISTS AND ANTAGONISTS
EE200000146A (en) Combination of monoamine oxidase inhibitor with h5-HT1B antagonist or partial agonist
PT1119359E (en) FORMULATION OF 2-METHYL-TIENE-BENZODIAZEPINE
FR2607004B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR
ID22060A (en) COMPOUNDS OF 2-IMIDAZOLINYLAMINOBENZOKSAZOL USE AS ADRENOSEPTOR AGONISTS
ES2168816T3 (en) INJECTION CEMENT CONTAINING CORROSION INHIBITORS.
ATE261434T1 (en) TRIPTOLIDE DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
NO995914L (en) Procedure for detecting the risk of thrombosis
FR2744621B1 (en) DETERMINATION OF FEMORAL AND TIBIAL TUNNELS FOR ISOMETRIC RECONSTRUCTION OF THE ANTERIOR CROSS LIGAMENT
DE29618426U1 (en) Structured contact surface for medical purposes
BR9704653A (en) Process for increasing the life span of dental components
DK0904070T3 (en) Use of the buckminster fuller for the treatment of neurotoxic lesions
NO20005386D0 (en) Use of NMDA antagonists for the treatment of irritable bowel syndrome
NO20010569D0 (en) Protease inhibitors for use in the treatment of psoriasis